Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)-Reference-Cited by-同舟云学术

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Published:2023-02-24 Issue:4 Volume:37 Page:924-928
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Stegelmann Frank^ORCID,Teichmann Lino L.^ORCID,Heidel Florian H.,Crodel Carl C.,Ernst Thomas^ORCID,Kreil Sebastian,Reiter Andreas,Otten Sara,Schauer Stefanie,Körber Ruth-Miriam,Kricheldorf Kim,Isfort Susanne,Döhner Hartmut^ORCID,Brümmendorf Tim H.^ORCID,Griesshammer Martin,Döhner Konstanze^ORCID,Koschmieder Steffen^ORCID

Funder

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-01837-9.pdf

Reference15 articles.

1. Ahlstrand E, Samuelsson J, Lindgren M, Pettersson H, Liljeholm M, Ravn-Landtblom A, et al. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up. Eur J Haematol. 2020;104:271–8.

2. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–13.

3. Stegelmann F, Wille K, Busen H, Fuchs C, Schauer S, Sadjadian P, et al. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Leukemia. 2021;35:628–31.

4. Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35:2592–601.

5. Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36:569–72.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options;Annals of Hematology;2024-03-04

2. BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing;Frontiers in Genetics;2023-09-08